Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum

Infection and Immunity

Volumn 73, Issue 11, 2005, Pages 7375-7380

  Arakawa, Takeshi ^a   Komesu, Ai ^a   Otsuki, Hitoshi ^b   Sattabongkot, Jetsumon ^c   Udomsangpetch, Rachanee ^d   Matsumoto, Yasunobu ^e   Tsuji, Naotoshi ^f   Wu, Yimin ^g   Torii, Motomi ^b   Tsuboi, Takafumi ^h  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

^e UNIVERSITY OF TOKYO   (Japan)

^f NATIONAL INSTITUTE OF ANIMAL HEALTH   (Japan)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h EHIME UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTISERUM; CHOLERA TOXIN; EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN SUBCLASS; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MEMBRANE PROTEIN; PROTEIN PFS25; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOPHELES; ANOPHELES DIRUS; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; GAMETOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; MALARIA; MALARIA CONTROL; MIDGUT; MOUSE; NONHUMAN; OOCYST; PARASITE ISOLATION; PICHIA PASTORIS; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN EXPRESSION; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ANTIGENS, SURFACE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; MICE, INBRED BALB C; OOCYSTS; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

EID: 27744520417     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.11.7375-7380.2005     Document Type: Article

References (33)

1. Arakawa, T., T. Tsuboi, A. Kishimoto, J. Sattabongkot, N. Suwanabun, T. Rungruang, Y. Matsumoto, N. Tsuji, H. Hisaeda, A. Stowers, I. Shimabukuro, Y. Sato, and M. Torii. 2003. Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes. Vaccine 21:3143-3148.
2. Barr, P. J., K. M. Green, H. L. Gibson, I. C. Bathurst, I. A. Quakyi, and D. C. Kaslow. 1991. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J. Exp. Med. 174:1203-1208.
3. Boyle, J. S., J. L. Brady, and A. M. Lew. 1998. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 392:408-411.
4. Breman, J. G., M. S. Alilio, and A. Mills. 2004. Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am. J. Trop. Med. Hyg. 71(2 Suppl.):1-15.
5. Carcaboso, A. M., R. M. Hernandez, M. Igartua, J. E. Rosas, M. E. Patarroyo, and J. L. Pedraz. 2004. Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine 22:1423-1432.
6. Carter, R. 2001. Transmission blocking malaria vaccines. Vaccine 19:2309-2314.
7. Coban, C., M. T. Philipp, J. E. Purcell, D. B. Keister, M. Okulate, D. S. Martin, and N. Kumar. 2004. Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations. Infect. Immun. 72:253-259.
8. Eriksson, A., and N. Lycke. 2003. The CTA1-DD vaccine adjuvant binds to human B cells and potentiates their T cell stimulating ability. Vaccine 22:185-193.
9. Eriksson, A. M., K. M. Schon, and N. Y. Lycke. 2004. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J. Immunol. 173:3310-3319.
10. Gozar, M. M., O. Muratova, D. B. Keister, C. R. Kensil, V. L. Price, and D. C. Kaslow. 2001. Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate. Exp. Parasitol. 97:61-69.
11. Gozar, M. M., V. L. Price, and D. C. Kaslow. 1998. Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice. Infect. Immun. 66:59-64.
12. Hagiwara, Y., T. Iwasaki, H. Asanuma, Y. Sato, T. Sata, C. Aizawa, T. Kurata, and S. Tamura. 2001. Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain. Vaccine 19:1652-1660.
13. Haneberg, B., and J. Holst. 2002. Can. nonliving nasal vaccines be made to work? Expert Rev. Vaccines 1:227-232.
14. Harandi, A. M., J. Sanchez, K. Eriksson, and J. Holmgren. 2003. Recent developments in mucosal immunomodulatory adjuvants. Curr. Opin. Investig. Drugs 4:156-161.
15. Hirunpetcharat, C., D. Stanisic, X. Q. Liu, J. Vadolas, R. A. Strugnell, R. Lee, L. H. Miller, D. C. Kaslow, and M. F. Good. 1998. Intranasal immunization with yeast-expressed 19 kD carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (yMSP119) induces protective immunity to blood stage malaria infection in mice. Parasite Immunol. 20:413-420.
16. Hisaeda, H., A. W. Stowers, T. Tsuboi, W. E. Collins, J. S. Sattabongkot, N. Suwanabun, M. Torii, and D. C. Kaslow. 2000. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect. Immun. 68:6618-6623.
17. Kaslow, D. C., I. A. Quakyi, C. Syin, M. G. Raum, D. B. Keister, J. E. Coligan, T. F. McCutchan, and L. H. Miller. 1988. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 333:74-76.
18. Kaslow, D. C., I. C. Bathurst, T. Lensen, T. Ponnudurai, P. J. Barr, and D. B. Keister. 1994. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect. Immun. 62:5576-5580.
19. Kongkasuriyachai, D., L. Bartels-Andrews, A. Stowers, W. E. Collins, J. Sullivan, J. Sattabongkot, M. Torii, T. Tsuboi, and N. Kumar. 2004. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy. Vaccine 22:3205-3213.
20. Lobo, C. A., R. Dhar, and N. Kumar. 1999. Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies. Infect. Immun. 67:1688-1693.
21. Malkin, E. M., A. P. Durbin, D. J. Diemert, J. Sattabongkot, Y. Wu, K. Miura, C. A. Long, L. Lambert, A. P. Miles, J. Wang, A. Stowers, L. H. Miller, and A. Saul. 2005. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23:3131-3138.
22. Niikura, M., S. Takamura, G. Kim, S. Kawai, M. Saijo, S. Morikawa, I. Kurane, T. C. Li, N. Takeda, and Y. Yasutomi. 2002. Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes. Virology 293:273-280.
23. Schorr, J., B. Knapp, E. Hundt, H. A. Kupper, and E. Amann. 1991. Surface expression of malarial antigens in Salmonella typhimurium: induction of serum antibody response upon oral vaccination of mice. Vaccine 9:675-681.
24. Somner, E. A., S. A. Ogun, K. A. Sinha, L. M. Spencer Valero, J. J. Lee, J. A. Harrison, A. A. Holder, C. E. Hormaeche, and C. M. Khan. 1999. Expression of disulphide-bridge-dependent conformational epitopes and immunogenicity of the carboxy-terminal 19 kDa domain of Plasmodium yoelii merozoite surface protein-1 in live attenuated Salmonella vaccine strains. Microbiology 145:221-229.
25. Tsuboi, T., Y. M. Cao, Y. Hitsumoto, T. Yanagi, H. Kanbara, and M. Torii. 1997. Two antigens on zygotes and ookinetes of Plasmodium yoelii and Plasmodium berghei that are distinct targets of transmission-blocking immunity. Infect. Immun. 65:2260-2264.
26. van der Lubben, I. M., G. Kersten, M. M. Fretz, C. Beuvery, J. Coos Verhoef, and H. E. Junginger. 2003. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 21:1400-1408.
27. Wang, L., L. Kedzierski, S. L. Wesselingh, and R. L. Coppel. 2003. Oral immunization with a recombinant malaria protein induces conformational antibodies and protects mice against lethal malaria. Infect. Immun. 71:2356-2364.
28. Watanabe, I., T. M. Ross, S. Tamura, T. Ichinohe, S. Ito, H. Takahashi, H. Sawa, J. Chiba, T. Kurata, T. Sata, and H. Hasegawa. 2003. Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin. Vaccine 21:4532-4538.
29. World Health Organization. 2002. Annex table 3: burden of disease in DALYs by cause, sex and mortality stratum in W.H.O. regions, estimates for 2001. World Health Report, 2002: reducing risks, promoting healthy life, 192-197. World Health Organization, Geneva, Switzerland.
30. Wu, S., M. Beier, M. B. Sztein, J. Galen, T. Pickett, A. A. Holder, O. G. Gomez-Duarte, and M. M. Levine. 2000. Construction and immunogenicity in mice of attenuated Salmonella typhi expressing Plasmodium falciparum merozoite surface protein 1 (MSP-1) fused to tetanus toxin fragment C. J. Biotechnol. 83:125-135.
31. Wu, Y., X. Wang, K. L. Csencsits, A. Haddad, N. Walters, and D. W. Pascual. 2001. M cell-targeted DNA vaccination. Proc. Natl. Acad. Sci. USA 98:9318-9323.
32. Yuki, Y., and H. Kiyono. 2003. New generation of mucosal adjuvants for the induction of protective immunity. Rev. Med. Virol. 13:293-310.
33. Zou, L., A. P. Miles, J. Wang, and A. W. Stowers. 2003. Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials. Vaccine 21:1650-1657.